All In Biotech

Drug Trial Radar · NCT07215273

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Elion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections

Conditions

  • Invasive Mould Infection

Interventions

  • EL219Drug

    EL219 is specifically being developed for early antifungal therapy (EAT), when infection is suspected due to highly suggestive signs and symptoms of disease; in high-risk people, antifungals are recommended even before confirmation of the microbial cause of infection, because delayed therapy is associated with poor outcomes in those who lack adequate immune responses. EL219 may provide a once-weekly alternative to LAmB and other polyenes that could also reduce the toxicities that often limit the frequency and duration of administration for these highly efficacious antifungals.

  • Active Comparator- IV Antifungal (LAmB or voriconazole)Drug

    LAmB has broad-spectrum activity but its use is limited by toxicity and once-daily IV administration. It is not administered outside of the monitored setting given risks for electrolyte disturbances and cardiac arrhythmias. Voriconazole is a first-line therapy for IA and the most common azole used in the US and globally but does not have activity against many non-Aspergillus moulds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome/Measure All-Cause MortalityTime frame: From enrollment to Day 21
  2. Primary Outcome/Measure SAE TEAETime frame: From enrollment to the end of treatment at Day 42

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • U. of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • UC Davis Medical Center

    Sacramento, California · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • John Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • U. of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington U.

    St Louis, Missouri · Recruiting

  • U. of Texas, MD Anderson

    Houston, Texas · Recruiting

  • U. of Texas Health Sciences Center at San Antonio

    San Antonio, Texas · Recruiting

  • U. of Washington

    Seattle, Washington · Recruiting

  • AZ Sint-Jan Brugge

    Bruges, Belgium · Recruiting

  • Universite Libre de Bruxelles (ULB) - Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Liege

    Liège, Belgium · Recruiting

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Juravinski Hospital

    Hamilton, Ontario, Canada · Recruiting

  • University Health Network (UHN) - Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier d'Argenteuil

    Argenteuil, France · Recruiting

  • AP-HP Hopital Henri Modor

    Créteil, France · Recruiting

  • AP-HP Hopital Saint-Louis

    Paris, France · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS- Universita Cattolica del Sacro Cuore

    Roma, Italy · Recruiting

  • Hospital del Mar

    Barcelona, Spain · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Clinic Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Spain · Recruiting

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.